DermTech Announces Appointment of General Counsel
January 05 2021 - 3:30PM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in
precision dermatology enabled by a non-invasive skin genomics
platform, announced today the appointment of Ray Akhavan to the
role of General Counsel. Akhavan will serve on the executive
leadership team and have responsibility for all legal, intellectual
property and compliance matters.
“Ray is the perfect fit for DermTech’s general counsel role
given his balanced experience in medical and consumer genomics, and
his foundation in science and intellectual property law,” commented
John Dobak, M.D., CEO of DermTech.
Akhavan has more than 16 years of experience that includes
private practice at a prominent international law firm, as well as
with leading companies in consumer genomics and cancer diagnostics.
Most recently, Akhavan served as Associate General Counsel and
Chief IP Counsel at Ancestry, and prior to that as General Counsel
and Chief IP Counsel at Caris Life Sciences. Akhavan’s experience
also includes working as a research biologist in the National
Institutes of Health, and as a patent examiner at the United States
Patent & Trademark Office. Akhavan was awarded a J.D. from
Washington College of Law at American University and an M.S. in
Molecular Biology from George Mason University.
Akhavan commented, “I’m very excited to join DermTech at this
pivotal time. I look forward to working with the team to maximize
DermTech’s potential in the genomic diagnostic space, currently
focusing on early non-invasive detection of melanoma and other skin
cancers using innovative cutting-edge technology.”
About DermTech:
DermTech is the leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by our non-invasive skin genomics platform. DermTech’s mission is
to transform the practice of dermatology through more accurate
diagnosis and treatment, and the elimination of unnecessary
surgery, leading to improved patient care and lower costs. DermTech
provides genomic analysis of skin samples collected non-invasively
using an adhesive patch rather than a scalpel. DermTech markets and
develops products that facilitate the early detection of skin
cancers, and is developing products that assess inflammatory
diseases and customize drug treatments. For additional information
on DermTech, please visit DermTech’s investor relations site at:
www.DermTech.com.
Forward-Looking Statements:
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations with respect to: the performance, patient
benefits, cost-effectiveness, commercialization and adoption of
DermTech’s products and the market opportunity therefor. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from the expected results. Most of these factors are
outside of the control of DermTech and are difficult to predict.
Factors that may cause such differences include, but are not
limited to: (1) the outcome of any legal proceedings that may be
instituted against DermTech; (2) DermTech’s ability to obtain
additional funding to develop and market its products; (3) the
existence of favorable or unfavorable clinical guidelines for
DermTech’s tests; (4) the reimbursement of DermTech’s tests by
Medicare and private payors; (5) the ability of patients or
healthcare providers to obtain coverage of or sufficient
reimbursement for DermTech’s products; (6) DermTech’s ability to
grow, manage growth and retain its key employees; (7) changes in
applicable laws or regulations; (8) the market adoption and demand
for DermTech’s products and services together with the possibility
that DermTech may be adversely affected by other economic,
business, and/or competitive factors; and (9) other risks and
uncertainties included in (x) the “Risk Factors” section of the
most recent Quarterly Report on Form 10‑Q filed by DermTech with
the Securities and Exchange Commission (the “SEC”), and (y) other
documents filed or to be filed by DermTech with the SEC. DermTech
cautions that the foregoing list of factors is not exclusive. You
should not place undue reliance upon any forward-looking
statements, which speak only as of the date made. DermTech does not
undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210105005954/en/
DermTech Sarah Dion sdion@dermtech.com 858.450.4222
Crowe PR Sarah Gallagher sgallagher@crowepr.com 224.406.4709
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Apr 2024 to May 2024
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From May 2023 to May 2024